Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/06—Antipsoriatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents

Definitions

• the invention relates to inhibitors of Janus Kinase 1 (JAK1), a process for synthesis of the compounds of the present invention, composition comprising the compounds and use of the compounds for inhibition of JAK1.
• JAK1 Janus Kinase 1
• Cytokines are key drivers of several biological pathways and anti-cytokine therapy is indicated if there is any dysregulation in the pathway.
• Signalling pathways for Type I and Type II cytokine receptors a family of receptors employed by over 50 cytokines, interleukins, interferons, colony stimulating factors, and hormones.
• Type I and Type II cytokine receptors are related by their mode of intracellular signaling: they all employ JAKs.
• Janus Kinases JAK
• JAK Janus Kinases
• JAK1, JAK2, JAK3 and Tyrosine Kinase 2 bind directly to the intracellular domains of Type I/II cytokine receptors and not to other classes of cytokine receptors.
• Different cytokine receptor families utilize specific JAK isoforms for signal transduction. Phosphorylation of JAK when cytokine binds to its cognate receptor leads to phosphorylation of other intracellular molecules that eventually leads to gene transcription.
• JAK-dependent cytokines are major contributors to immunopathology and that blocking such cytokines with biologics can be beneficial in immune-mediated diseases and in cancers and several other major disease and disorders.
• JAK1 plays a key role in types I and II interferon signaling and elicits signals from the interleukin-2, interleukin-4, gp130 and class II receptor families. As such, small molecule inhibition of JAK1 may intervene in the signaling pathways involved in oncology, inflammation and autoimmune diseases. However, to minimize adverse effects, especially those arising from JAK2 inhibition, the generation of selective inhibitors could in principle maintain efficacy and improve safety.
• An object of the invention is to provide compounds as selective JAK1 inhibitor, a process for preparation of the inhibitors, a composition containing the compounds and utility of the compounds.
• the present invention discloses 1H-imidazo[4,5-b]pyridin-2(3H)-one as selective inhibitor of JAK 1 their pharmaceutically acceptable salts and isomers of formula I:
• A is a 5 membered or a 6 membered carbocycle or heterocycle comprising 1 to 3 heteroatom selected from the group comprising O, N, S optionally substituted with CH3, F or Cl;
• B is H or alkoxy or O, -CO-, optionally substituted 3 to 8 carbocyclic ring, 3 to 8 membered heterocyclic ring containing 1 to 3 heteroatoms selected from the group comprising O, N, S,
• X is independently, H, (CH 2 )n, -CO-, OCO, COO; CO(CH 2 )n, (NH 2 )n; (CH 2 )n(NH 2 )n; (CH 2 )n(NH 2 )nCN; CONH; CONR 1 R 2 , CO(NH 2 )n; (CH 2 )nCO(NH 2 )n, CO(NH 2 )n(CH 2 )CF 3 , SO 2 (CH 2 )n, NH(CH 2 )nCN, unsubstituted
• Figure 1 depicts cumulative Psoriasis Score and body weight of Example 1133 and 1215 in IMQ induced psoriasis mouse model.
• the present invention discloses 1H-imidazo[4,5-b]pyridin-2(3H)-one as selective inhibitor of JAK 1 their pharmaceutically acceptable salts and isomers of formula I:
• A is a 5 membered or a 6 membered carbocycle or heterocycle comprising 1 to 3 heteroatom selected from the group comprising O, N, S optionally substituted with CH 3 , F or Cl;
• B is H or alkoxy or O, -CO-, optionally substituted 3 to 8 carbocyclic ring, 3 to 8 membered heterocyclic ring containing 1 to 3 heteroatoms selected from the group comprising O, N, S,
• X is independently, H, (CH 2 )n, -CO-, OCO, COO; CO(CH 2 )n, (NH 2 )n; (CH 2 )n(NH 2 )n; (CH 2 )n(NH 2 )nCN; CONH; CONR 1 R 2 , CO(NH 2 )n; (CH 2 )nCO(NH 2 )n, CO(NH 2 )n(CH 2 )CF 3 , SO 2 (CH 2 )n, NH(CH 2 )nCN, unsubstit
• the compounds disclosed herein and their pharmaceutically acceptable salts can exist as single stereoisomers, racemates, and as mixtures of enantiomers and diastereomers.
• the compounds disclosed herein can also exist as geometric isomers. All such single stereoisomers, racemates and mixtures thereof, and geometric isomers are intended to be within the scope of the compounds disclosed herein.
• the compounds of the present invention include: 1001. N-(2,2,2-trifluoroethyl)-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-7- yl)benzamide;
• B is H;
• X is independently, H, (CH 2 )n, -CO-, OCO, COO; CO(CH 2 )n, (NH 2 )n; (CH 2 )n(NH 2 )n; (CH 2 )n(NH 2 )nCN; CONH; CONR 1 R 2 , CO(NH 2 )n; (CH 2 )nCO(NH 2 )n, CO(NH 2 )n(CH 2 )CF 3 , SO 2 (CH 2 )n, NH(CH 2 )nCN, unsubstituted or substituted 3-8 membered carbocylic ring or heterocyclic ring containing 1 to 3 heteroatoms selected from the group comprising O, N, S and SO 2 , and substituents on the carboxylic or heterocyclic ring may be selected from Halogen, Alkoxy, CHMe, -CH(CF 3 ), -C(CF 3 )(OH), C(CF 3 )(OMe), -CH(CN
• Y may be present at any position of the pyridine ring, preferably, at 4 th or 5 th position of pyridine; Y is H, R 1 , R 2 , halo, CN, -CO-, COR 1 , (CH 2 )n, -(CH 2 )nCN -, CH 2 CF 3 , COOH, -COOR 1 , - CON(R 1 ) 2 ,-SO 2 (CH 2 )n,-SO 2 N(R 1 ) 2 , -OCOR 1 , -NR 1 COR 1 , -CONH, CONR 1 R 2 , - CO(NH 2 )n(CH 2 )nSO 2 ; -CONH(CH 2 )nOH, CONH(CH 2 )nSO 2 R 1 R 2 , -CONH-(CH 2 )nCF 3 , - CONH(CH 2 )nCF 3 ,-NHCONH(CH 2 )nCF 3 , , ,
• substitution may independently be R 1 and R 2 at any position of the heterocyclic ring; C 1-6 alk-aryl, Ar C 1-6 alkyl; R 1 and R 2 are absent or independently selected from the group comprising H, halo, CN, CF 3 , hydroxyl, Amino, SO 2 , SO 2 C 1 -C 6 Alkyl, CH 2 CF 3 , C 1 -C 6 straight or branched alkyl, C 1 -C 6 straight or branched alkenyl, C 1 -C 6 straight or branched alkynyl, halo-C 1 -C 6 alkyl, C 1 -C 6 alkyloxy; C 1 -C 6 alkylamino, n is 0 to 3.
• the present invention discloses exemplary compounds of formula III as below: 1133.1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro- 1-(1-methylpiperidin-4-yl)ethanol; 1134.1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro- 1-(tetrahydro-2H-pyran-4-yl)ethanol; 1176.1-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole-1-carbonyl)pyrrolidine-3- carbonitrile 1181.7-(1-(5-((S)-1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyri
• the present invention also discloses a process of preparing the compounds of the present invention.
• the compounds of the present invention can be prepared by the general synthetic schemes 1 to 4, presented here below: General Synthetic Scheme 1:
• X is C, N, R 2 and R 3 is H, R1:
• X is C, N,
• R 1 is CN and R 2 is H R3;
• X is C, N,
• R 1 CF 3 and R 2 is H, R 3 ;
• X is C, N,
• R 1 is CF 3 and R 2 is OH R3
• X is C, N,
• R1 is CF3 and R2 is OCH3 R 3
• X 1 O or H
• R 2 H or–CH 3
• R 3 H or–CH 3 R 1 ;
• X1, Y, Z is C, N.
• R 3 is H, O, carbocycle,
• X is C, N.
• the invention also comprises as another embodiment, a composition comprising a JAK1 inhibitor compound according to any one of the preceding embodiments together with a pharmaceutically acceptable diluent, excipient, and/or carrier.
• the compositions will include a conventional pharmaceutical carrier, excipient, and/or diluent and a compound of this disclosure as the/an active agent, and, in addition, can include carriers and adjuvants, etc.
• the pharmaceutically acceptable compositions will contain about 1% to about 99% by weight of a compound(s) of this disclosure, or a pharmaceutically acceptable salt thereof, and 99% to 1% by weight of a suitable pharmaceutical excipient.
• administration can be, for example, orally, nasally, parenterally (intravenous, intramuscular, or subcutaneous), topically, transdermally, intravaginally, intravesically, intracisternally, or rectally, in the form of solid, semi-solid, lyophilized powder, or liquid dosage forms, such as for example, tablets, suppositories, pills, soft elastic and hard gelatin capsules, powders, solutions, suspensions, or aerosols, or the like, preferably in unit dosage forms suitable for simple administration of precise dosages.
• Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. Solid dosage forms, as described above, can be prepared with coatings and shells, such as enteric coatings.
• Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs.
• Compositions for rectal administrations are, for example, suppositories that can be prepared by mixing the compounds of this disclosure with, for example, suitable non-irritating excipients or carriers. They are also be parenteral and administered as sterile powders for reconstitution into sterile injectable solutions or dispersions.
• Dosage forms for topical administration of a compound of this disclosure include ointments, powders, sprays.
• Ophthalmic formulations, eye ointments, powders, inhalation formulations and solutions are also contemplated for the compounds in this disclosure.
• Compressed gases can be used to disperse a compound of this disclosure in aerosol form.
• the invention comprises as a further embodiment a method for treating a disease JAK1 mediates or is implicated in a subject in need thereof comprising administrating to the subject a therapeutically effective amount of a JAK1 inhibitor compound according to any one of the preceding embodiments, or a composition comprising a JAK1 inhibitor according to any one of the preceding embodiments together with a pharmaceutically acceptable diluent, excipient, and/or carrier.
• the diseases JAK1 mediates or is implicated in that may be treated includes, without limitation, cancer, inflammatory disorders, and autoimmune diseases.
• the selective JAK1 inhibitors of the present invention may be effective in treating cancer, including, but not limited to, carcinomas, sarcomas, lymphomas, leukemias, myelomas, germ cell tumors, blastomas, tumors of the central and peripheral nervous system and other tumors including melanomas, seminoma and Kaposi's sarcoma and the like.
• the compounds of the present invention may also be useful in disorder and diseases pertaining to acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, asthma, autoimmune hemolytic anemia, autoimmune thyroiditis, Crohn's disease, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, Goodpasture's syndrome, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome and other interbowel diseases, Lupus, myasthenia gravis, myocardial or pericardial inflammation, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, scleroderma, systemic analphylaxis, ulcerative colitis, nephritis (including glomerulonephritis), gout, arthritis (such as rheumatoid arthritis and osteo
• the compounds of the present invention exhibit selective inhibition of JAK1 with respect to JAK 2, JAK 3 and TYK 2. Therefore, it is submitted that the compounds of the present invention demonstrate selective inhibition and therefore are more specific and advantageous than other compounds in prior art, as they are expected to result in less adverse effects.
• the examples and scheme below depict the general synthetic procedure for the compounds disclosed herein. Synthesis of the compounds of Formulae I disclosed herein, and embodiments thereof, are not limited by these examples and schemes. One skilled in the art will know that other procedures can be used to synthesize the compounds of Formulae I disclosed herein, and that the procedures described in the examples and schemes is only one such procedure.
• Step-1 Synthesis of tert-butyl 3-hydroxypyrrolidine-1-carboxylate:
• Step-1 Synthesis of tert-butyl 3-carbamoylcyclobutylcarbamate:
• Step-5 synthesis of N-(3-cyanocyclobutyl)-4-(2,3-dihydro-2-oxo-1H-imidazo[4,5- b]pyridin-7-yl)-1H-pyrazole-1-carboxamide
• Step-1 Synthesis of 4-(2-amino-3-nitropyridin-4-yl)-N-(2,2,2-trifluoroethyl)-1H- pyrazole-1-carboxamide
• Step-5 Synthesis of 4-(1-(5-(2,2,2-trifluoro-1-methoxyethyl)pyridin-2-yl)-1H-pyrazol-4- yl)pyridine-2,3-diamine
• Step-6 Synthesis of 7-(1-(5-(2,2,2-trifluoro-1-methoxyethyl)pyridin-2-yl)-1H-pyrazol-4- yl)-3H-imidazo[4,5-b]pyridine
• Step-1 Synthesis of N-methoxy-N-methyl cyclopropane carboxamide:
• Step-5 Synthesis of 1-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-1- cyclopropyl-2,2,2-trifluoroethanol
• Step-6 Synthesis of 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3- yl)-1-cyclopropyl-2,2,2-trifluoroethanol
• Step-1 Synthesis of N-methoxy-N-methyl cyclopropane carboxamide:
• Step-7 Synthesis of (6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3- yl)(1-(methylsulfonyl)piperidin-4-yl)methanone
• Step-8 Synthesis of 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3- yl)-1-cyclopropyl-2,2,2-trifluoroethanol
• Step-2 Synthesis of 6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl) pyridine-3- carbaldehyde
• Step-4 2-(6-(4- diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-(1,1-
• Step-1 Synthesis of 1-(6-bromopyridin-3-yl)-3-(methylthio)propan-1-ol:
• Step-7 Synthesis of 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3- yl)-4-(methylsulfonyl)butanenitrile
• Step-2 Synthesis of methyl 6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridine- 3-carboxylate
• Step-6 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)nicotinoyl)azetidine-3- carbonitrile
• Step-6 Synthesis of 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3- yl)propanenitrile :
• Step-1 Synthesis of 2-(6-bromopyridin-3-yl)-2-cyclopropylacetonitrile:
• reaction mixture was diluted with H 2 O: EtOAc (50 mL, 5:5) and pass over celite to remove inorganic impurities from the reaction mixture.
• the aqueous layer was extracted with ethyl acetate.
• the organic layer was washed with water, brine, dried over sodium sulphate and concentrated under reduced pressure to obtained pure 2-(6-(4-(2,3- diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-cyclopropyl-N-(2,2,2- trifluoroethyl)acetamide (0.061g, 82.43%) as dark brown solid mass.
• Step-6 Synthesis of 2-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3- yl)-2-cyclopropyl-N-(2,2,2-trifluoroethyl)acetamide:
• Step-5 Synthesis of 2-bromo-5-(2,2,2-trifluoro-1-(oxetan-3-yl)ethyl)pyridine
• Step-7 Synthesis of 4-(1-(5-(2,2,2-trifluoro-1-(oxetan-3-yl)ethyl)pyridin-2-yl)-1H- pyrazol-4-yl)pyridine-2,3-diamine
• reaction mixture was diluted with H 2 O: EtOAc (50 mL, 5:5) and pass over celite to remove inorganic impurities from the reaction mixture.
• the aqueous layer was extracted with ethyl acetate.
• the organic layer was washed with water, brine, dried over sodium sulphate and concentrated under reduced pressure to obtained pure 4-(1-(5-(2,2,2-trifluoro-1-(oxetan-3- yl)ethyl)pyridin-2-yl)-1H-pyrazol-4-yl)pyridine-2,3-diamine (0.032g, 69.56%) as dark brown solid mass.
• Step-8 Synthesis of 7-(1-(5-(2,2,2-trifluoro-1-(oxetan-3-yl)ethyl)pyridin-2-yl)-1H- pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine
• Step-1 Synthesis of 1-(6-bromopyridin-3-yl)ethanol :
• Step-4 Synthesis of 4-(1-(5-(1-(methylsulfonyl)ethyl)pyridin-2-yl)-1H-pyrazol-4-yl)-3- nitropyridin-2-amine
• Step-5 Synthesis of 4-(1-(5-(1-(methylsulfonyl)ethyl)pyridin-2-yl)-1H-pyrazol-4- yl)pyridine-2,3-diamine:
• Step-1 Synthesis of S-3-(6-bromopyridin-3-yl)-4,4,4-trifluorobutyl ethanethioate:
• Step-4 Synthesis of 3-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3- yl)-4,4,4-trifluoro-N-methylbutane-1-sulfonamide
• reaction mixture was diluted with H 2 O: EtOAc (50 mL, 5:5) and pass over celite to remove inorganic impurities from the reaction mixture.
• the aqueous layer was extracted with ethyl acetate.
• the organic layer was washed with water, brine, dried over sodium sulphate and concentrated under reduced pressure to obtained pure 3-(6-(4-(2,3- diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluoro-N-methylbutane-1- sulfonamide (0.045g, 69.23%) as dark brown solid mass.
• Step-6 Synthesis of 3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3- yl)-4,4,4-trifluoro-N-methylbutane-1-sulfonamide:
• Step-1 Synthesis of 2-bromo-5-(1-bromo-3-(methylthio)propyl)pyridine:
• Step-6 Synthesis of 4-(1-(5-(3-(methylsulfonyl)-1-(oxetan-3-yl)propyl)pyridin-2-yl)-1H- pyrazol-4-yl)-3-nitropyridin-2-amine :
• Step-7 Synthesis of 4-(1-(5-(3-(methylsulfonyl)-1-(oxetan-3 ridin-2-yl)-1H-
• reaction mixture was diluted with H 2 O: EtOAc (50 mL, 5:5) and pass over celite to remove inorganic impurities from the reaction mixture.
• the aqueous layer was extracted with ethyl acetate.
• the organic layer was washed with water, brine, dried over sodium sulphate and concentrated under reduced pressure to obtained pure 4-(1-(5-(3- (methylsulfonyl)-1-(oxetan-3-yl)propyl)pyridin-2-yl)-1H-pyrazol-4-yl)pyridine-2,3-diamine (0.045g, 80.35%) as dark brown solid mass.
• Step-8 Synthesis of 7-(1-(5-(3-(methylsulfonyl)-1-(oxetan-3-yl)propyl)pyridin-2-yl)-1H- pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine :
• Step-1 Synthesis of 1-(6-bromopyridin-2-yl)-2,2,2-trifluoroethanone:
• Step-6 Synthesis of 4-(1-(6-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)- 1H-pyrazol-4-yl)-3-nitropyridin-2-amine:
• Step-7 Synthesis of 4-(1-(6-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)- 1H-pyrazol-4-yl)pyridine-2,3-diamine:
• reaction mixture was diluted with H 2 O: EtOAc (50 mL, 5:5) and pass over celite to remove inorganic impurities from the reaction mixture.
• the aqueous layer was extracted with ethyl acetate.
• the organic layer was washed with water, brine, dried over sodium sulphate and concentrated under reduced pressure to obtained pure 4-(1-(6-(1,1,1-trifluoro-4- (methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)pyridine-2,3-diamine (0.036g, 75%) as dark brown solid mass.
• Step-8 Synthesis of 7-(1-(6-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)- 1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine :
• Step-1 Synthesis of 1-(2-bromopyridin-4-yl)-2,2,2-trifluoroethanone:
• Step-5 Synthesis of 4-(1-(4-(4-bromo-1,1,1-trifluorobutan-2-yl)pyridin-2-yl)-1H-pyrazol- 4-yl)-3-nitropyridin-2-amine
• Step-6 Synthesis of 4-(1-(4-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)- 1H-pyrazol-4-yl)-3-nitropyridin-2-amine:
• Step-7 Synthesis of 4-(1-(4-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)- 1H-pyrazol-4-yl)pyridine-2,3-diamine:
• reaction mixture was diluted with H 2 O: EtOAc (50 mL, 5:5) and pass over celite to remove inorganic impurities from the reaction mixture.
• the aqueous layer was extracted with ethyl acetate.
• the organic layer was washed with water, brine, dried over sodium sulphate and concentrated under reduced pressure to obtained pure 4-(1-(4-(1,1,1-trifluoro-4- (methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)pyridine-2,3-diamine (0.036g, 75%) as dark brown solid mass.
• Step-8 Synthesis of 7-(1-(4-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)- 1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine:
• Step-1 Synthesis of 4-nitrophenyl cyclopropylcarbamate:
• Step-4 Synthesis of 1-(1-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3- yl)-2,2,2-trifluoroethyl)-3-cyclopropylurea
• reaction mixture was diluted with H2O: EtOAc (50 mL, 5:5) and pass over celite to remove inorganic impurities from the reaction mixture.
• the aqueous layer was extracted with ethyl acetate.
• the organic layer was washed with water, brine, dried over sodium sulphate and concentrated under reduced pressure to obtained pure 1-(1-(6-(4-(2,3- diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoroethyl)-3-cyclopropylurea (0.045g, 56.96%) as dark brown solid mass.
• Step-6 Synthesis of 1-(1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1- yl)pyridin-3-yl)-2,2,2-trifluoroethyl)-3-cyclopropylurea:
• Step-1 Synthesis of 1-(3-(6-bromopyridin-3-yl)-4,4,4-trifluorobutyl)-3-cyclopropylurea :
• Step-2 Synthesis of 1-(3-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3- yl)-4,4,4-trifluorobutyl)-3-cyclopropylurea
• reaction mixture was diluted with H 2 O: EtOAc (50 mL, 5:5) and pass over celite to remove inorganic impurities from the reaction mixture.
• the aqueous layer was extracted with ethyl acetate.
• the organic layer was washed with water, brine, dried over sodium sulphate and concentrated under reduced pressure to obtained pure 1-(3-(6-(4-(2,3- diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutyl)-3-cyclopropylurea (0.042g, 75%) as dark brown solid mass.
• Step-4 Synthesis of 1-(3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1- yl)pyridin-3-yl)-4,4,4-trifluorobutyl)-3-cyclopropylurea:
• Step-1 Synthesis of ethyl 2-aminooxazole-4-carboxylate
• Step-7 Synthesis of 2-(2-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)oxazol-4- yl)acetonitrile
• Step-1 Synthesis of (6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3- yl)methanol:
• Step-3 synthesis of 2-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3- yl)acetonitrile
• Step-1 Synthesis of N-(2,2,2-trifluoroethyl)-4-(2-phenyl-3H-imidazo[4,5-b]pyridin-7-yl)- 1H-pyrazole-1-carboxamide:
• Step-1 Synthesis of tert-butyl 4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazole-1- carboxylate:
• Step-3 Synthesis of tert-butyl 4-(2-phenyl-3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazole- 1-carboxylate:
• Step-5 Synthesis of 3-cyclopentyl-3-(4-(2-phenyl-3H-imidazo[4,5-b]pyridin-7-yl)-1H- pyrazol-1-yl)propanenitrile:
• Step-1 Synthesis of (E/Z)-ethyl 3-(6-bromopyridin-3-yl)-4,4,4-trifluorobut-2-enoate
• Step-4 Synthesis of 4-(1-(5-(4-bromo-1,1,1-trifluorobutan-2-yl)pyridin-2-yl)-1H-pyrazol- 4-yl)-3-nitropyridin-2-amine
• Step-6 Synthesis of 4-(1-(5-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)- 1H-pyrazol-4-yl)pyridine-2,3-diamine:
• reaction mixture was diluted with H 2 O: EtOAc (50 mL, 5:5) and pass over celite to remove inorganic impurities from the reaction mixture.
• the aqueous layer was extracted with ethyl acetate.
• the organic layer was washed with water, brine, dried over sodium sulphate and concentrated under reduced pressure to obtained pure 4-(1-(5-(1,1,1-trifluoro-4- (methylsulfonyl)butan-2-yl)pyridin-2-yl)-1H-pyrazol-4-yl)pyridine-2,3-diamine (0.036g, 75%) as dark brown solid mass.
• Step-7 Synthesis of 7-(1-(5-(1,1,1-trifluoro-4-(methylsulfonyl)butan-2-yl)pyridin-2-yl)- 1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine:
• Step-1 Synthesis of 1-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)- 2,2,2-trifluoroethanol
• Step-2 synthesis of 2-(1-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3- yl)-2,2,2-trifluoroethoxy)acetonitrile
• reaction mixture was diluted with H 2 O: EtOAc (50 mL, 5:5) and filtered through celite to remove inorganic impurities from the reaction mixture.
• the aqueous layer was extracted with ethyl acetate.
• the organic layer was washed with water, brine, dried over sodium sulphate and concentrated under reduced pressure to obtained pure 2-(1-(6-(4-(2,3- diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoroethoxy)acetonitrile (0.040 g, 86.9 %) as dark brown solid mass.
• Step-5 Synthesis of 4-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-N- cyclopropyl-5,5,5-trifluoropentanamide
• reaction mixture was diluted with H 2 O: EtOAc (50 mL, 5:5) and filtered through celite to remove inorganic impurities from the reaction mixture.
• the aqueous layer was extracted with ethyl acetate.
• the organic layer was washed with water, brine, dried over sodium sulphate and concentrated under reduced pressure to obtained pure 4-(6-(4-(2,3- diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-N-cyclopropyl-5,5,5- trifluoropentanamide (0.040 g, 85.4 %) as dark brown solid mass.
• Step-6 Synthesis of 4-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3- yl)-N-cyclopropyl-5,5,5-trifluoropentanamide
• Step-1 Synthesis of N-methoxy-N-methyl cyclopropane carboxamide:
• Step-3 Synthesis of tert-butyl 4-(1-(6-bromopyridin-3-yl)-2,2,2-trifluoro-1- hydroxyethyl)piperidine-1-carboxylate
• Step-4 Synthesis of tert-butyl 4-(1-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1- yl)pyridin-3-yl)-2,2,2-trifluoro-1-hydroxyethyl)piperidine-1-carboxylate
• Step-7 Synthesis of 1-(4-(1-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3- yl)-2,2,2-trifluoro-1-hydroxyethyl)piperidin-1-yl)ethenone
• reaction mixture was diluted with H 2 O: EtOAc (50 mL, 5:5) and pass over celite to remove inorganic impurities from the reaction mixture.
• the aqueous layer was extracted with ethyl acetate.
• the organic layer was washed with water, brine, dried over sodium sulphate and concentrated under reduced pressure to obtained 1-(4-(1-(6-(4- (2,3-diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1- hydroxyethyl)piperidin-1-yl)ethanone (0.025 g, 78.12 %) as dark brown solid mass.
• Step-1 Synthesis of 1-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)- 2,2,2-trifluoro-1-(1-methylpiperidin-4-yl)ethanol
• reaction mixture was diluted with H 2 O: EtOAc (50 mL, 5:5) and pass over celite to remove inorganic impurities from the reaction mixture.
• the aqueous layer was extracted with ethyl acetate.
• the organic layer was washed with water, brine, dried over sodium sulphate and concentrated under reduced pressure to obtained 1-(6-(4-(2,3- diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,2,2-trifluoro-1-(1-methylpiperidin-4- yl)ethanol (0.040 g, 71.4 %) as dark brown solid mass.
• Step-3 Synthesis of 1-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1-yl)pyridin-3- yl)-2,2,2-trifluoro-1-(1-methylpiperidin-4-yl)ethanol
• Step-1 Synthesis of 1-(6-bromopyridin-3-yl)-2,2,2-trifluoroethanone:
• Step-7 Synthesis of N-(3-(6-(4-(2-amino-3-nitropyridin-4-yl)-1H-pyrazol-1-yl)pyridin- 3-yl)-4,4,4-trifluorobutyl)methanesulfonamide
• reaction mixture was diluted with H 2 O: EtOAc (50 mL, 5:5) and pass over celite to remove inorganic impurities from the reaction mixture.
• the aqueous layer was extracted with ethyl acetate.
• the organic layer was washed with water, brine, dried over sodium sulphate and concentrated under reduced pressure to obtained pure N-(3-(6-(4-(2,3- diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutyl)methanesulfonamide (0.025 g, 75%) as dark brown solid mass.
• Step-1 Synthesis of 1-(6-bromopyridin-3-yl)-2,2,2-trifluoroethanone
• Step-2 Synthesis of (E/Z)-ethyl 3-(6-bromopyridin-3-yl)-4,4,4-trifluorobut-2-enoate
• Step-3 Synthesis of 3-(6-bromopyridin-3-yl)-4,4,4-trifluorobutan-1-ol :
• Step-4 Synthesis of 2-bromo-5-(4-bromo-1,1,1-trifluorobutan-2-yl)pyridine
• Crude product was purified by silica gel (100-200 mesh) column chromatography using 5 to 7% Acetone in Hexane as eluent to obtain 2-bromo-5-(4-bromo- 1,1,1-trifluorobutan-2-yl)pyridine (0.300 g, 47.05 %) as reddish colour semi solid.
• Step-7 Synthesis of tert-butyl 3-(6-(4-(2,3-diaminopyridin-4-yl)-1H-pyrazol-1- yl)pyridin-3-yl)-4,4,4-trifluorobutylmethylcarbamate:
• reaction mixture was diluted with H 2 O: EtOAc (50 mL, 5:5) and pass over celite to remove inorganic impurities from the reaction mixture.
• the aqueous layer was extracted with ethyl acetate.
• the organic layer was washed with water, brine, dried over sodium sulphate and concentrated under reduced pressure to obtained pure tert-butyl 3-(6-(4-(2,3- diaminopyridin-4-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-4,4,4-trifluorobutylmethylcarbamate (0.036g, 75%) as dark brown solid mass.
• Step-8 Synthesis of tert-butyl 3-(6-(4-(3H-imidazo[4,5-b]pyridin-7-yl)-1H-pyrazol-1- yl)pyridin-3-yl)-4,4,4-trifluorobutylmethylcarbamate:
• JAK1, JAK2, JAK3 and TYK2 were used to develop biochemical assays in 50 mM HEPES pH 7.5, 1 mM EGTA, 10 mM MgCl 2 , 2 mM DTT and 0.01% Tween-20. Amount of enzyme, substrate (ULigh-JAK-1 (Tyr1023) Peptide and ATP concentrations to be used was determined for each kinase assay by respective titration and Km studies. Biochemical assay was developed by LANCE Ultra TR-FRET technology (Perkin Elmer). Enzyme and compounds were incubated at 22 o C for 60 minutes in a white 384 well optiplate (Perkin Elmer).
• TF-1 cells were starved overnight in OptiMEM medium with 0.5% charcoal stripped fetal bovine serum, 0.1mM nonessential amino acids (NEAA), 1mM sodium pyruvate and without phenol red in CO 2 incubator maintained at 37 o c.
• NEAA nonessential amino acids
• cells were resuspended in RPMI without phenol red and dispensed into a 96 well plate at a final cell density of 1,20,000 cells per well.
• Compounds were diluted in DMSO and added to cells and incubated for 30 minutes in CO 2 incubator maintained at 37 o c. Final DMSO concentration in cell based assay was 0.2%.
• HT-2 cells were starved overnight in RPMI phenol red with 10% fetal bovine serum for 4 hours in CO 2 incubator maintained at 37 o c.
• Compounds were diluted in DMSO and added to 96 well plate containing a final density of 1,20,000 cells per well. Cells and compounds are incubated for 30 minutes in CO 2 incubator maintained at 37 o c and final DMSO concentration in cell based assay was 0.2%.
• Human recombinant cytokine, IL-2 (50U/ml) was added to the plate containing cells and compound and incubated for 20 minutes with gentle tapping / shaking at every 5 minutes once.
• NK 92 cells were cultured in medium without IL-2 for overnight. Next day, 5000 cells per well NK 92 cells were seeded in a 96 well plate. Compounds were added to cells and incubated for 1 hour. Later IL-12, 10U/ml was added to cells and incubated for overnight. Supernatant was collected from the wells and IFN-g secretion was measured by using human IFN-g ELISA kit. Absorbance was measured at 450nm in BMG FLUOstar. Background signal obtained from cells which were not activated with cytokines, was subtracted from vehicle controls and compound treated wells. Percentage inhibition of IFN-g secretion by compounds were calculated from vehicle controls, which were considered as 100% IFN-g secretion.
• Example 1133, 1181 and 1215 showed better potency as well as selectivity for JAK1 (7 to 80 fold selective for JAK1 vs JAK2; 3 to 22 fold selective for JAK1 vs JAK3) compared to filgotinib (0.9 fold JAK1 vs JAK2; 12 fold JAK1 vs JAK3). These compounds are also far superior in terms of JAK1 selectivity compared to a pan inhibitor such as tofacitinib.
• Biological Example 6 Mouse model of Rheumatoid arthritis:
• Rheumatoid arthritis is an autoimmune disease that can cause joint pain and damage throughout the body.
• cytokines such as IL-6 and IFN-g activate the Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway. Inhibition of JAK/STAT pathway is considered as one of the therapeutic options for treatment of rheumatoid arthritis.
• Rodent models of arthritis can be used to evaluate the therapeutic potential of compounds dosed preventatively or therapeutically. These models include but are not limited to mouse or rat collagen-induced arthritis, rat adjuvant-induced arthritis, and collagen antibody-induced arthritis.
• Imiquimod (IMQ) induced dermatitis closely resembles human psoriasis lesions not only with regard to phenotypic and histological characteristics but also in the development of the lesions.
• IMQ is a ligand for toll-like receptor 7 (TLR7) and TLR8, and is a potent immune activator.
• TLR7 and TLR8 immunomodulatory effects in triggering psoriasis are attributed to stimulation of TLR7 and TLR8 on plasmacytoid dendritic cells (pDCs) and an upregulated type I interferon pathway. Migration of activated dermal dendritic cells to lymph nodes in skin triggers a sequence of events leading to late phase of psoriasis.
• Example 1133, Example 1215 and filgotinib showed statistically significant decrease in cumulative psoriasis score compared to vehicle. There was a significant decrease in back skin thickness, ear thickness on administration of Example 1133, 1215 and filgotinib (3% topical, QD).
• Example 1215 showed better efficacy compared to 1133 and reference compound filgotinib.
• the data is represented by way of a Figure 1. From the figure, it can be clearly seen that there the exemplary compounds of the present invention show enhanced efficacy when compared to the compounds available in the market such Filgotinib.
• the animal in which the colitis is produced can be any mammal and can include but is not limited to mouse, rat, guinea pig, hamster, rabbit, cat, dog, goat, monkey, and chimpanzee.
• the colitis can be produced in the animal by any method known in the art.
• a mouse model of oxazolone induced colitis was utilized to study the efficacy of JAK inhibitors.
• Oxazolone colitis has a histological resemblance to human ulcerative colitis.
• Pro-inflammatory cytokines elevated in ulcerative colitis rely on JAK family of tyrosine kinases for signal transduction. It has been proposed that JAK inhibition may be beneficial in the treatment of ulcerative colitis.
• mice Male BALB/c mice were used in the study., 10-12 weeks, on day 1, 4% Oxazolone (in 4:1 acetone: olive oil formulation) or vehicle solution was applied between shoulders to anesthetized animals. Seven days after skin sensitization, mice were fasted for 6 hours prior to intra-rectal administration of 1% oxazolone (in 1:1 ethanol:water formulation). Drug treatment or vehicle administration (PO, BID) was initiated on day 6, a day prior to intra-rectal oxazolone challenge. Animals were dosed with test compounds or vehicle till day 9. Disease activity index (DAI) was graded for each mouse by treatment-blinded experimenters.
• DAI Disease activity index
• Example 1181, 1215 and filgotinib showed statistically significant decrease in disease activity index compared to vehicle. There was a significant decrease in stool consistency, rectal bleeding and body weight loss parameters on administration of Example 1181, 1215 and filgotinib (30mpk, PO, BID). Example 1215 showed better efficacy in comparison to the marketed compound Filgotinib.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Rheumatology (AREA)
• Immunology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Physical Education & Sports Medicine (AREA)
• Dermatology (AREA)
• Pain & Pain Management (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Plural Heterocyclic Compounds (AREA)

Priority Applications (9)

Applications Claiming Priority (2)

Publications (1)

Family

ID=73553608

Family Applications (1)

Country Status (11)

Cited By (6)

Citations (4)

Family Cites Families (14)

• 2020
  • 2020-05-26 AU AU2020284742A patent/AU2020284742B2/en active Active
  • 2020-05-26 CA CA3141571A patent/CA3141571A1/en active Pending
  • 2020-05-26 EP EP20812987.4A patent/EP3976612A4/en active Pending
  • 2020-05-26 WO PCT/IN2020/050471 patent/WO2020240586A1/en not_active Ceased
  • 2020-05-26 US US17/614,114 patent/US12516056B2/en active Active
  • 2020-05-26 BR BR112021023635A patent/BR112021023635A2/pt unknown
  • 2020-05-26 MX MX2021014361A patent/MX2021014361A/es unknown
  • 2020-05-26 CN CN202080054241.8A patent/CN114174294B/zh active Active
  • 2020-05-26 JP JP2021570725A patent/JP7592029B2/ja active Active
  • 2020-05-27 TW TW109117600A patent/TWI839524B/zh active
• 2021
  • 2021-11-17 ZA ZA2021/09183A patent/ZA202109183B/en unknown

Patent Citations (4)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events